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Background: Despite the recognised contribution of the stroma to breast cancer development and progression, the effective
targeting of the tumor microenvironment remains a challenge to be addressed. We previously reported that normal
fibroblasts (NFs) and, notably, breast cancer-associated fibroblasts (CAFs) induced epithelial-to-mesenchymal transition
and increases in cell membrane fluidity and migration in well- (MCF-7) and poorly-differentiated (MDA-MB-231) breast
cancer cells. This study was designed to better define the role played, especially by CAFs, in promoting breast tumor cell
migration.
Methods: Fibroblast/breast cancer cell co-cultures were set up to investigate the influence of NFs and CAFs on gene and
protein expression of Stearoyl-CoA desaturase 1 (SCD1), the main enzyme regulating membrane fluidity, as well as on the
protein level and activity of its transcription factor, the sterol regulatory element-binding protein 1 (SREBP1), in MCF-7 and
MDA-MB-231 cells. To assess the role of SREBP1 in the regulation of SCD1 expression, the desaturase levels were also
determined in tumor cells treated with an SREBP1 inhibitor. Migration was evaluated by wound-healing assay in SCD1-
inhibited (by small-interfering RNA (siRNA) or pharmacologically) cancer cells and the effect of CAF-conditioned medium was
also assessed. To define the role of stroma-derived signals in cancer cell migration speed, cell-tracking analysis was performed
in the presence of neutralising antibodies to hepatocyte growth factor, transforming growth factor-b or basic fibroblast growth
factor.
Results: A two to three fold increase in SCD1 mRNA and protein expression has been induced, particularly by CAFs, in the two
cancer cell lines that appear to be dependent on SREBP1 activity in MCF-7 but not in MDA-MB-231 cells. Both siRNA-mediated
and pharmacological inhibition of SCD1 impaired tumor cells migration, also when promoted by CAF-released soluble factors.
Fibroblast-triggered increase in cancer cell migration speed was markedly reduced or abolished by neutralising the above growth
factors.
Conclusion: These results provide further insights in understanding the role of CAFs in promoting tumor cell migration, which may
help to design new stroma-based therapeutic strategies.
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Over the last decade, research on breast cancer, as well as on other
solid tumours, has progressively focused on the elucidation of the
intricate web of intercellular interactions occurring between the
transformed epithelium and the tumor stroma, composed of
mesenchyme-derived cells such as fibroblasts, myofibroblasts,
pericytes, endothelial and inflammatory cells. A growing body of
experimental evidence indicates that changes taking place in the
stromal environment surrounding malignant cells, also called
‘reactive stroma’, may have strong functional implications for
breast tumor development and progression (Polyak and Kalluri,
2010; Tarin, 2013). These stromal alterations concern gene
expression, extracellular matrix deposition/remodelling and secre-
tion of soluble factors, among others (Lebret et al, 2007; Polyak and
Kalluri, 2010; Tarin, 2013; Gialeli et al, 2014). In turn, transformed
epithelial cells undergo ‘epithelial-to-mesenchymal transition’
(EMT), a reversible switch from a polarised, adherent phenotype
to a more motile and invasive one, mainly driven by integrated
signalling from the heterogeneous population of ‘cancer-associated
fibroblasts’ (CAFs) which represent the major cell type of the
reactive tumor stroma (Lebret et al, 2007; Tarin, 2013). On the
basis of gene-expression profile and phenotype, CAFs can be
distinguished from resting normal fibroblasts. They release growth
factors (e.g., SDF-1a, VEGF, HGF, EGF, FGFs, TGF-b, PDGF),
pro-tumorigenic inflammatory signals and matrix metalloproteases
promoting angiogenesis, tumor cell proliferation and invasiveness
(Lebret et al, 2007; Liao et al, 2009; Ostman and Augsten, 2009;
Sadlonova et al, 2009; Erez et al, 2013; Gialeli et al, 2014).
Tumorigenicity of CAFs derived from breast cancers has been
widely demonstrated in animal models (Camps et al, 1990;
Kuperwasser et al, 2004; Orimo et al, 2005). Induction of
mammary cancers has been reported in mice orthotopically
grafted with TGF-b- and/or HGF-transfected fibroblasts, co-
injected with apparently normal epithelial cells, highlighting the
critical role of heterotypic interactions in the development of
human breast malignancies (Kuperwasser et al, 2004).
Among the various cancer cell signatures, the improvement of
the invasive/metastatic tumor cell ability might be considered one
of the major outcome of this aberrant dialogue with CAFs (Hu
et al, 2008; Wang et al, 2013). In various human malignancies this
increased migratory skill of tumor cells, as well as poor prognosis,
significantly correlates with alterations in the motional freedom of
lipids and protein molecules in the plasma membrane. In
particular, malignant cell membranes have been found to generally
exhibit higher fluidity than that of their healthy counterparts
(Nakazawa and Iwaizumi, 1989; Taraboletti et al, 1989; Zeisig et al,
2007).
We have recently shown by co-cultures of mammary cancer
cells and fibroblasts their reciprocal influence on various
adhesiveness and/or invasiveness features (Angelucci et al, 2012).
Most notably, an overall pro-tumoral/-invasive effect of CAFs on
both well- and poorly-differentiated breast cancer cells has been
demonstrated by the induction of EMT and by the increase in
membrane fluidity, as well as in migration speed and directness
(Angelucci et al, 2012).
Saturated fatty acids (SFAs) and monounsaturated fatty acids
(MUFAs) are essential elements of membrane phospholipids,
regulators of the membrane fluidity and crucial cell signalling
mediators controlling various cellular activities (Faergeman and
Knudsen, 1997; Tang et al, 2002). Alterations in the balance of
SFAs and MUFAs can therefore influence a wide variety of cell
functions. Stearoyl-CoA desaturase 1 (SCD1), an endoplasmic
reticulum-resident D9 deasaturase, is one of the main enzyme
regulating the fatty acid membrane composition. It catalyses the
endogenous biosynthesis of MUFAs from de novo synthesised or
dietary SFAs and has been recently raised to the role of key
regulator of cell growth, programmed cell death and carcinogenesis
(Igal, 2011). Abnormally high levels of SCD1 have been reported in
human cancers, carcinogen-induced tumours and virus-trans-
formed cells, where the resulting increase in MUFA membrane
content has been shown to match with an enhanced membrane
fluidity (Li et al, 1994; Thai et al, 2001; Scaglia et al, 2005). In
breast cancer cells, pharmacological inactivation or genetic
knockdown of SCD1 impairs cancer cell growth and inhibits
glucose-mediated lipogenesis (Scaglia et al, 2009; Luyimbazi et al,
2010). A more loosely packed state of cancer cell membranes has
also been reported to correlate with increased migratory capacity
(Nakazawa and Iwaizumi, 1989; Taraboletti et al, 1989). This latter
activity is influenced by paracrine signals too. In particular, the
crucial role of CAF-released growth factors such as hepatocyte
growth factor/scatter factor (HGF), transforming growth factor-b
(TGF-b) or basic fibroblast growth factor (bFGF) in promoting
invasive behaviour of breast tumor cells has been demonstrated
(Giulianelli et al, 2008; Jedeszko et al, 2009; Stuelten et al, 2010;
Cao et al, 2013). This effect well illustrates the dialogue existing
between epithelial cancer cells and CAFs in breast tumor milieu.
Indeed, the fibroblast contribution to tumor progression through
paracrine signalling is, in turn, attributable to the cancer cell ability
in altering fibroblast nature, realizing a sort of genome reprogram-
ming of these stromal cells that are ‘instructed’ to secrete pro-
tumorigenic soluble factors (Stuelten et al, 2010; Tyan et al, 2011).
The present study was designed to gain further insight into the
molecular mechanisms responsible for the fibroblast-elicited
alterations of cancer cell membrane fluidity and ability to migrate
that we previously reported (Angelucci et al, 2012).
With this aim, we co-cultured poorly invasive/low metastasising
or highly invasive and metastatic breast cancer cells (MCF-7 and
MDA-MB-231, respectively) with fibroblasts isolated from mam-
mary healthy skin (normal fibroblasts (NFs)) or from breast tumor
stroma (CAFs). In accordance with the formerly demonstrated
enhancement in cancer cell membrane fluidity induced by NFs or
CAFs (Angelucci et al, 2012), here, we report the ability of
fibroblasts to upregulate SCD1 expression. In low invasive tumor
cells, this latter effect was mediated by the CAF-triggered induction
of the SCD1 transcription factor, sterol regulatory element-binding
protein 1 (SREBP1). To assess the alleged involvement of SCD1 in
the fibroblast-triggered improvement of cancer cell migration
(Angelucci et al, 2012), both siRNA knockdown and pharmaco-
logic inhibition of SCD1 was performed in cancer cells with a
resulted impairment of their migratory ability. Finally, evaluation
of cancer cell migration speed in tumor cell/fibroblast co-cultures
in the presence of neutralising antibodies to HGF, TGF-b or bFGF,
provides evidence of the crucial contribution of these CAF-derived
diffusible signals to the CAF promotion of cancer cell motility that
we have previously shown (Angelucci et al, 2012). In support of
this latter data, as well as the crucial role of SCD1 in tumor cell
migration, we found that the increase in cancer cell motility
induced by the treatment with CAF-conditioned medium was
suppressed as a result of the SCD1 pharmacological inhibition.
MATERIALS AND METHODS
Clinical specimens and fibroblast cultures. Primary normal
mammary skin fibroblasts (NFs) and CAFs were isolated and
immunocytochemically assayed to validate their fibroblastic nature
as previously described (Angelucci et al, 2012). NFs and CAFs were
maintained in Dulbecco’s Modified Eagle’s Medium (DMEM;
Euroclone, Milan, Italy) supplemented with 10% foetal bovine
serum (FBS; Life Technologies, Carlsbad, CA, USA), antibiotics
(100 IUml 1 penicillin, 100 mgml 1 streptomycin, Euroclone),
2mM glutamine (Euroclone) and 1mM sodium pyruvate (Euro-
clone). Cells were incubated at 37 1C in a humidified atmosphere of
5% CO2-95% air.
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Co-culture experiments were carried out with fibroblasts of
passage 2–3 to avoid cell-aging effects.
Breast cancer cell lines. The estrogen receptor (ER)-positive,
poorly invasive and low metastasising human breast carcinoma cell
line MCF-7 and the ER-negative, highly invasive and metastatic
human breast carcinoma cell line MDA-MB-231 were obtained
from American Type Culture Collection (Manassas, VA, USA).
MCF-7 and MDA-MB-231 cells were maintained in DMEM
(Euroclone) supplemented with 10% FBS (Life Technologies,
Paisley, Scotland), antibiotics (100 IUml 1 penicillin, 100 mgml 1
streptomycin, Euroclone) and 2mM glutamine (Euroclone). Cells
were incubated at 37 1C in a humidified atmosphere of 5% CO2-
95% air.
Co-cultures. For the evaluation of SCD1 expression, SREBP1
activity/expression and cell migration speed, co-cultures of
fibroblasts and tumor epithelial cells were performed. Briefly,
subconfluent fibroblast and breast cancer cell cultures were
trypsinized and B5 103 per cm2 cells of each cell type were
plated together in their standard medium in 100mm Petri dishes
(for the evaluation of SCD1 expression or SREBP1 activity and
expression) or in 35mm glass-bottom Petri dishes (ibidi GmbH,
Martinsried, Germany) for cell-tracking analysis of cell migration
speed. Medium was renewed after 3 days and all the above analyses
were carried out after 6 days, as described below. MCF-7 and
MDA-MB-231 homotypic cultures were used as controls.
Separation of breast cancer cells from the co-cultures. Cells of
6-day monolayer cultures and co-cultures were collected to
investigate the influence of NFs and CAFs on SCD1 mRNA and
protein level, as well as on SREBP1 protein expression and DNA
binding activity in breast cancer cells. Cells in mixed cultures were
separated by magnetic cell sorting (EasySep Magnet, StemCell
Technologies, Vancouver, BC, Canada) using the Human ‘Do-It-
Yourself’ Positive Selection Kit (StemCell Technologies) with an
anti-fibroblast antibody (anti-human CD90, Thy-1, clone 5E10,
StemCell Technologies), according to the manufacturer’s
instructions. An aliquot of the eluted tumor cell fraction of the
co-cultures were analysed by immunoblotting for the expression
of the chemokine stromal-derived factor 1 (SDF-1), a marker of
cells of mesenchymal origin, in order to determine possible
fibroblastic contamination before carrying out quantitative
real-time PCR (qRT-PCR) and Western blotting analyses
(Supplementary Figure S1).
qRT-PCR. Because the levels of mammalian SCD1 appear to be
principally determined by its rate of transcription (Ntambi et al,
2004), we investigated the effect produced by fibroblasts on the
desaturase mRNA level in breast cancer cells by qRT-PCR.
Briefly, total RNA was extracted from MCF-7 or MDA-MB-231
cells cultured alone or co-cultured with fibroblasts (NFs or CAFs)
for 6 days with the RNAqueous-4PCR kit (Ambion, Austin, TX,
USA), according to the manufacturer’s instructions. In all 2mg of
RNA was converted into single-stranded DNA by a standard 50-ml
RT reaction with the TaqMan RT Reagent (Life Technologies). The
cDNA generated from the reverse transcription reactions was
amplified by PCR with the TaqMan Gene-expression Assays (Life
Technologies) in a total volume of 25 ml. The reactions were
incubated at 50 1C for 2min, 95 1C for 20 s, followed by 40 cycles of
95 1C for 1 s and 60 1C for 20 s, on a StepOne Real-Time PCR
Systems (Life Technologies). The primers used were as follows: 50-
CTC CAC TGC TGG ACA TGA GA-30 (forward), 50-AAT GAG
TGAAGG GGC ACA AC-30 (reverse); b-actin: 50-ATC TGG CAC
CAC ACC TTC-30 (forward) and 50-AGC CAG GTC CAG ACG
CA-30 (reverse). The level of SCD1 mRNA was expressed as
relative fold change vs the b-actin mRNA. The relative fold change
in mRNA expression was calculated using the 2DDCt method,
where the average of DCt values for SCD1 amplicon was
normalised to that of b-actin, compared with control (MCF-7 or
MDA-MB-231 cells cultured alone). Reactions were performed in
triplicate.
Western blot analysis. For SDF-1 and SCD1 analysis, total
protein extracts were obtained by lysing tumor cells in RIPA
buffer (50mM Tris-HCl (pH 7.7), 150mM NaCl, 1% Triton X-100,
1% sodium deoxycholate, 0.1% SDS) freshly supplemented
with phosphatase and protease inhibitors (100 mM Na3VO4,
0.3mM phenylmethylsulfonylfluoride, 50mgml 1 leupeptin and
20 mgml 1 aprotinin). To evaluate the expression level of the
nuclear mature form of SREBP1, nuclear proteins were extracted
using NE-PER Nuclear and Cytoplasmic Extraction Reagents
(Thermo Fisher Scientific, Waltham, MA, USA). In all 30 mg of
total or nuclear proteins were resolved on a 10% SDS-PAGE and
transferred onto Immobilon P membrane (Millipore, Bedford, MA,
USA) which was incubated with anti-SDF-1 antibody (Abcam,
Cambridge, UK, 1 : 1000), anti-SCD1 antibody (clone M38, Cell
Signaling Technology, Danvers, MA, USA, 1 : 2000), or anti-
SREBP1 antibody (clone C20, Santa Cruz Biotechnology, Santa
Cruz, CA, 1 : 200). The blot was then overlaid with a HRP-labelled
secondary antibody (Vector Laboratories, Burlingame, CA, USA;
1 : 3000 dilution). The protein bands were detected using an
enhanced chemiluminescence system (ECL, GE Healthcare,
Piscataway, NJ, USA) and visualised on Hyperfilm ECL (GE
Healthcare). As internal loading control, antibodies to b-actin
(clone AC15, Sigma-Aldrich, St. Louis, MO, USA, 1 : 10000) and
Lamin A/C (clone 14, BD Transduction Laboratories, 1 : 1000)
were used for cytosolic (SDF-1 and SCD1) and nuclear (mature
active form of SREBP1) targets proteins, respectively. Band
intensities were measured by densitometry (Chemi Doc Docu-
mentation System/Quantity One quantitation software, Bio-Rad
Laboratories Inc, Hercules, CA, USA). Variations in SCD1 or
SREBP1 protein levels were expressed as fold change compared
with control (MCF-7 or MDA-MB-231 cells cultured alone) after
normalisation to b-actin or Lamin A/C expression.
SREBP1 transcription factor activity. To evaluate the influence
of NFs and CAFs on the transcription of SCD1 gene in tumor cells,
the ability of the mature form of SREBP1 to bind to the SREBP
response elements (SREs) on the SCD1 promoter was assayed in
MCF-7 or MDA-MB-231 cells cultured alone or co-cultured with
fibroblasts for 6 days using an enzyme-linked immunosorbent
assay (ELISA; human SREBP1 Transcription Factor Assay Kit,
Cayman Chemical, Ann Arbor, MI, USA), according to the
manufacturer’s instructions. Cancer cell nuclear proteins were
extracted using NE-PER Nuclear and Cytoplasmic Extraction
Reagents (Thermo Fisher Scientific).
Small-interfering RNA. The silencing of SCD1 gene was achieved
by using small-interfering RNA (siRNA) duplex oligonucleotides
against the coding sequence of human SCD1 cDNA that were
synthesised and purchased by Integrated DNA Technologies
(Coralville, IA, USA). We selected two target sequences as follows:
50-AAU GAU CAG AAA GAG CCG UAG-30 (sense_SCD1_1) and
50AAA UCG UCU CCA ACU UAU CUC-30 (sense_SCD1_2).
Transfection of 60 pmol siRNA in MCF-7 and MDA-MB-231 cells
was carried out by using Oligofectamine Transfection Reagent
(0.3%, v/v; Life Technologies), according to the manufacturer’s
instructions. Fresh medium was added 5 h after transfection and
cells were further incubated for 72 h. Commercial non-targeting
control siRNA NC1 (Integrated DNA Technologies) served as
experimental control.
The efficiency of SCD1 downregulation by siRNA was
demonstrated by Western blot analysis (Supplementary Figure S2).
Small-molecule inhibitor treatments. The small-molecule inhi-
bitor of SCD1 (4-(2-chlorophenoxy)-N-(3-(methylcarbamoyl)-
phenyl)piperidine-1-carboxamide; A939572, Biofine International,
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Vancouver, BC, Canada) was dissolved in DMSO and used at a
concentration of 1mM to inhibit SCD1 activity in MCF-7 or MDA-
MB-231 cells. Briefly, in order to evaluate the effect of SCD1 on
tumor cell motility (see ‘Wound-Healing Assay’ below) cells were
seeded in sixwell plates and grown to subconfluence in their
standard medium. They were incubated with 1mM A939572 or with
vehicle (0.01% DMSO, control cells) in serum-free DMEM and the
wound closure was evaluated after 24 and 48 h.
In order to evaluate the possible involvement of SCD1 on CAF-
promoted tumor cell migration, in a further series of experiments
the scratched tumor cell cultures were exposed to the CAF-
conditioned medium (CAF-CM), with or without the addition of
the SCD1 inhibitor (1 mM), and cell migration evaluated after 24
and 48 h.
To assess the contribution of SREBP1 to the effect induced by
CAF-released soluble factors on tumor cell SCD1 expression, the
desaturase protein levels were evaluated in MCF-7 and MDA-MB-
231 cells exposed to the CAF-CM, with or without the addition of
Fatostatin, a small-molecule inhibitor of SREBP activation (Sigma-
Aldrich). Briefly, cells were treated for 6 days with 0.2% (v/v)
DMSO (vehicle), CAF-CM with 0.2% (v/v) DMSO or 20 mM
Fatostatin. SCD1 expression was then determined by Western
blotting, as described above.
Wound-healing assay. In order to verify the effect of the genetic
knockdown or pharmacological inhibition of SCD1 on tumor cell
motility, a wound-healing assay was performed on MCF-7 and
MDA-MB-231 cells transfected with siRNA or treated with the
SCD1 inhibitor A939572 (in a series of experiments this latter
treatment was also performed on cells exposed to CAF-CM, as
described in the previous section). Cells were seeded in sixwell
plates and grown to subconfluence. Cell proliferation was blocked
by a 2 h pretreatment with mitomycin C (5 mgml 1) in serum-free
medium. A scratch was then made in each well using a 200 ml
pipette tip and the wounded monolayers washed twice with PBS to
remove cell debris and floating cells. The wounds (5 randomly
selected points per wound) were photographed at the beginning
(time 0) and then after 24, and 48 h under an inverted microscope
with a digital camera and the distance migrated by the cells was
measured at the reference points by an image-processing software
(ImageJ, open source from National Institutes of Health, Bethesda,
MD, USA). Three independent experiments were performed with
two sets of culture dishes for each condition.
Growth factor neutralization and cell-tracking experiments. To
study the effect of HGF, TGF-b and bFGF neutralization on the
fibroblast-induced increase in cancer cell migration speed, anti-
HGF, -TGF-b and -bFGF antibodies were added (alone or
combined) to the media of tumor cell cultures and co-cultures
(with NFs or CAFs) and tumor migration speed evaluated by single
cell-tracking of living cells and time-lapse confocal microscopy, as
previously described (Angelucci et al, 2012). Cultures and co-
cultures in which tumor cells were labelled with the CellTracker
Green CMFDA (Life Technologies) were set up in 35mm glass-
bottom Petri dishes (ibidi GmbH). Cells were allowed to grow to
30%–40% confluence in complete medium. Then the cells were
incubated in 0.5% FBS-containing DMEM in either the presence or
absence of the selected neutralising antibody (monoclonal mouse
anti-human HGF, 30 mgml 1; polyclonal rabbit anti-human TGF-
b, 50 mgml 1; polyclonal goat anti-human bFGF, 10mgml 1,
R&D Systems, Minneapolis, MN, USA) or control non-immune
IgGs (mouse, rabbit or goat nIgG, 50 mgml 1, R&D Systems) over
the last 48 h prior to perform cell-tracking. Migration speed of
CMFDA-labelled tumor cell was evaluated and analysed by using
the ImageJ software plugin ‘Particle Tracker’ and’Chemotaxis and
migration tool’as previously described (Angelucci et al, 2012). On
average 40 cells were tracked per experiment over a time period of
45min. The time interval between consecutive frames was 1min.
Once the analysis region was defined by means of the feature point
detection and tracking algorithm, each cell was numbered and its
(x(ti), y(ti)) position coordinates measured for each time point
ti (i¼ 1,y., N¼ 45). The instantaneous migration velocity and the
mean migration velocity ov4 for each cell was calculated as
v tið Þ ¼
ffiffiffiffiffiffiffiffiffiffiffiffiffiffi
v2ixþv2iy
q
where vix and viy were calculated according to
the expression:
vix ¼ x tiþ1ð Þx tið Þ½ 
tiþ1ti ; viy ¼
y tiþ1ð Þy tið Þ½ 
tiþ1ti
Where (x(tiþ 1), y(tiþ 1), (x(ti), y(ti))) are the positions of each cell
at the time tiþ 1 and ti. The mean migration velocity ov4 was
calculated according to the expression:
ov4 ¼ 1
N
X
i
v tið Þ:
Statistical analysis. At least three independent experiments were
performed for each protocol. The two-tailed Student’s t-test was
used to compare means of two different groups. The level of
significance was set at Po0.05.
RESULTS
Breast CAFs promote SCD1 gene and protein expression in
tumor cells. To shed light on the molecular basis of the previously
observed increase induced by NFs and CAFs in cancer cell plasma
membrane fluidity and migration (Angelucci et al, 2012), we co-
cultured MCF-7 and MDA-MB-231 cells with NFs or CAFs and
investigated the effect of such interaction on SCD1 gene and
protein expression in cancer cells. As a result of a 6-day co-culture
with NFs or CAFs, a significant induction of SCD1 transcript levels
was observed in both MCF-7 and MDA-MB-231 cells (Figure 1A
and C). The effect was particularly pronounced in tumor cells co-
cultured with CAFs in which a two to threefold enhancement of
SCD1 mRNA levels was detected if compared to the control
cultures (MCF-7 or MDA-MB-231). Likewise, interactions with
fibroblasts induced a statistically significant increase in SCD1
protein expression in tumor cells (Figure 1B and D). As described
for gene expression, CAFs showed to be endowed with a higher
ability to enhance SCD1 protein levels in cancer cells (by over
twofold, compared with control cultures). It is worth pointing out
that the efficacy of NFs in promoting SCD1 expression at both
mRNA and protein level seemed to undergo a decline in the higher
invasive and metastatic breast cancer cells (MDA-MB-231), if
compared with MCF-7 cells.
Breast CAFs differentially affect SREBP1 protein expression and
promote SREBP1 DNA binding activity in tumor cells. To
identify an upstream target in the control of cancer cell membrane
fluidity and migration exerted notably by CAFs, we carried out
Western blotting and ELISA and evaluated protein expression and
DNA binding activity of the SCD1 transcription factor (SREBP1)
in breast cancer cells after 6 days of co-culture with NFs or CAFs.
As far as SREBP1 protein expression is concerned, interaction
with fibroblasts seemed to produce a divergent effect in the two
cancer cell models (Figure 2A and C). In the ER-positive and
poorly invasive MCF-7 cells, a statistically significant increase (up
to B40% compared with control) in SREBP1 protein level was
induced, especially as a result of the interaction with CAFs
(Figure 2A). Conversely, the co-culture with fibroblasts promoted a
downregulation (30–40% compared with control) of SREBP1 in
the highly invasive MDA-MB-231 cells (Figure 2C). Consistent
with the data from Western blotting (Figure 2A), in MCF-7 cells
co-cultured with fibroblasts the DNA binding activity of SREBP1
also underwent a significant increase, mainly as a consequence of
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co-culture with CAFs (Figure 2B). Despite the reduction in
SREPB1 protein level triggered by fibroblasts in MDA-MB-231
cells, an increase rather than a decrease in the transcription factor
DNA binding activity was induced in these cells especially by CAFs
(Figure 2D).
SREBP1 pharmacological inhibition impairs CAF-mediated
induction of SCD1 expression in poorly invasive but not in
highly invasive breast cancer cells. In order to verify the role
played by SREBP1 in the CAF-triggered effect on SCD1 expression
in tumor cells, the desaturase protein levels were determined by
Western blotting in MCF-7 and MDA-MB-231 cells treated with
CAF-CM in the presence of 20 mM Fatostatin, an inhibitor of
SREPB activation. Exposure of both cell lines to CAF-CM
produced a pronounced enhancement of SCD1 levels, comparable
to that induced by the co-culture with CAFs (Figure 3). In MCF-7
cells, this effect was completely abolished by the co-incubation with
Fatostatin, demonstrating a crucial role for SREBP1 in mediating
the CAF-triggered desaturase upregulation (Figure 3A). Conver-
sely, in MDA-MB-231 cells, no significant alteration of the CAF-
induced increase in SCD1 expression was observed as a result of
Fatostatin treatment (Figure 3B).
SCD1 genetic inactivation and pharmacological inhibition
impair tumor cell migratory ability. The CAF-triggered increase
in SCD1 expression is consistent with the CAF-mediated
enhancement of cancer cell membrane fluidity and migration that
we have previously demonstrated (Angelucci et al, 2012). Thus, to
assess the possible contribution of SCD1 to breast cancer cell
migration, both siRNA-mediated inactivation and pharmacological
inhibition of the enzyme were performed in MCF-7 and MDA-
MB-231 cells and their migratory activity was evaluated by wound-
healing assay. At 24 and 48 h after wounding, a significant
reduction in cell migration ability was observed in MCF-7 and
MDA-MB-231 cells whose SCD1 expression was either pharma-
cologically or genetically inhibited (Figure 4A and B, respectively).
Because of the poorly invasive phenotype of MFC-7 cells, at 24 h
the impairing effect of both A939572 and siRNA on cell migration
was not so striking as at 48 h, when SCD1-depleted cells exhibited a
significant reduction in the migrated distance, if compared with
control cells (Figure 4A and B, left panels). As expected, in the
highly invasive MDA-MB-231 control cells a higher migration rate
was observed and a nearly complete or total wound closure was
found 48 h after scratching. In these cells, both genetic and
pharmacological SCD1 blockade resulted in a dramatic decline of
cell migration compared with uninhibited controls (Figure 4A and
B, right panels).
In the experiments in which tumor cells were exposed to CAF-
CM, a promoting effect of CAF-derived soluble factors on both
MCF-7 and MDA-MB-231 cell migration has been found. This
effect was completely suppressed by the pharmacological inhibition
of SCD1 (Figure 5).
HGF-, TGF-b and bFGF-neutralising antibodies reduce or
abolish the migration-promoting effect of CAFs. To test
whether secreted endogenous HGF, TGF-b and bFGF directly
contribute to the fibroblast-triggered enhancement of cancer cell
migration speed that we have previously described (Angelucci et al,
2012), cell-tracking experiments were performed on tumor cells
co-cultured with NFs or CAFs in the presence of antibodies
directed against HGF, TGF-b or bFGF.
The addition of the HGF neutralising antibody to the co-culture
media proved to be effective in counteracting the fibroblast-elicited
increase in tumor cell migration speed (Figure 6A and B). As far as
MCF-7 cells are concerned, both the NF- and CAF-triggered
migration-promoting effects were significantly reduced by the
addition of the anti-HGF antibody (Figure 6A), whereas they were
completely abolished in MDA-MB-231/fibroblast co-cultures
(Figure 6B).
The effects of TGF-b neutralization in MCF-7/ or MDA-MB-
231/fibroblast co-cultures were almost superimposable to those
described for HGF (Figure 6C and D).
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Figure 1. NFs and CAFs promote SCD1 gene and protein expression in tumor cells. (A, C) Analysis of SCD1 mRNA expression by qRT-PCR in
the poorly invasive MCF-7 cells (A) or in the highly invasive MDA-MB-231 cells (C) co-cultured for 6 days with NFs or CAFs revealed a
significant NF- or CAF-induced enhancement of SCD1 transcript levels as compared with control (ctrl, MCF-7 or MDA-MB-231 cells cultured
alone). (B, D) Densitometric analysis of SCD1 protein expression in MCF-7 (B) or MDA-MB-231 cells (D) co-cultured for 6 days with NFs or CAFs
(left panels) and representative Western blotting results (right panels). SCD1 protein levels were increased in both the tumor cell lines co-cultured
with NFs or CAFs as compared with the ctrl (MCF-7 or MDA-MB-231 cells cultured alone). Variations in SCD1 mRNA and protein levels were
expressed as fold change compared with control after normalisation to b-actin expression. All experiments were run in triplicate and repeated
three times. The data shown are the mean±s.e. *Po0.05 and **Po0.001 vs ctrl, Student’s t-test.
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The use of a neutralising antibody to bFGF led to a suppression
or a significant reduction of the increase in MCF-7 cell migration
speed induced by NFs or CAFs, respectively (Figure 6E). In the
highly invasive MDA-MB-231 cells co-cultured with fibroblasts,
the migration-promoting effects induced by both NFs and CAFs
were completely nullified by the treatment with an anti-bFGF
antibody (Figure 6F), as was found for HGF and TGF-b
neutralization.
Neither additive nor synergistic effects were observed when the
three neutralising antibodies were simultaneously added to the co-
cultures (Figure 6G and H).
Overall, results obtained in MCF-7 cells suggest that HGF might be
the major factor involved in the CAF-induced promotion of tumor
cell migration speed, whereas for the highly invasive MDA-MB-231
cells the three growth factors seem to almost equally contribute.
In all the experiments, treatment with nIgG had no effect on
fibroblast-induced promotion of cancer cell migration (Figure 6A-H).
Interestingly, none of the neutralising antibodies used seemed to
affect the basal migration rate of MCF-7 cells (Supplementary
Figure S3A, S3C and S3E), suggesting a critical paracrine
contribution by tumor stroma to the observed improvement in
cancer cell migratory skill. Conversely, neutralization of each of the
three secreted growth factors resulted in a certain reduction of the
basal migration speed of MDA-MB-231 cells (Supplementary
Figure S3B, S3D and S3F), which, as expected, was higher than that
of MCF-7. This finding seems to indicate that also autocrine HGF,
TGF-b and bFGF signalings might contribute, albeit to a lesser
extent, to migration in these highly invasive tumor cells.
DISCUSSION
In breast cancer research, the critical supporting role of the tumor
microenvironment as a source of signalling promoting tumor cell
growth and invasiveness has been increasingly recognised (Polyak
and Kalluri, 2010; Tarin, 2013).
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Figure 2. NFs and CAFs oppositely regulate SREBP1 expression and promote DNA binding activity in MCF-7 and MDA-MB-231 cells. Nuclear
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analysed by both Western blotting and human SREBP1 transcription factor assay. Fibroblasts, especially CAFs, induced an increase in both SREBP1
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Figure 3. SREBP1 pharmacological inhibition impairs CAF-mediated
induction of SCD1 expression in poorly invasive but not in highly
invasive breast cancer cells. Analysis of SCD1 protein expression by
Western blot analysis in the poorly invasive MCF-7 cells (A) or in the
highly invasive MDA-MB-231 cells (B) treated for 6 days with 0.2% (v/v)
DMSO (vehicle), CAF-conditioned medium (CAF-CM) with 0.2% (v/v)
DMSO or 20mM Fatostatin (Fato). Densitometric analysis (A and B, left
panels) revealed a significant CAF-induced enhancement of SCD1
levels as compared with control (ctrl, MCF-7 or MDA-MB-231 cells
treated with vehicle), which is antagonised by the inhibition of SREBP1
activation by Fatostatin, in MCF-7 (A) but not in MDA-MB-231 cells (B).
Representative Western blots are shown in the right panels. Variations
in SCD1 protein levels were expressed as fold change compared with
control after normalisation to b-actin expression. The data shown are
the mean±s.e. of two independent experiments run in triplicate.
ns¼ not significant; *Po0.01 and **Po0.002, Student’s t-test.
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We have recently reported the reciprocal influence of mammary
cancer cells and fibroblasts isolated from mammary skin or tumor
stroma on structural and functional aspects of their adhesion and
migratory phenotype (Angelucci et al, 2012). Notably, CAFs have
been demonstrated to induce EMT-related molecular changes, as
well as increases in cell membrane fluidity and motility in both
well- and poorly-differentiated breast cancer cells (Angelucci et al,
2012). Hence, this study was aimed to clarify the role played
notably by CAFs in improving breast tumor cell migratory ability
through the investigation of the expression/activity of upstream
potential effectors, as well as of the influence of paracrine
signalling.
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In this report, we demonstrated the major contribution of SCD1
and secreted growth factors to the fibroblast-mediated promotion
of cancer cell migration we have previously described (Angelucci
et al, 2012). To the best of our knowledge, this is the first study
demonstrating the ability of NFs and CAFs to induce an
enhancement of both transcript and protein levels of SCD1. By
steadily converting SFA into MUFA, SCD1 can be considered the
main enzyme regulating lipid bilayer fluidity. In addition, its key
role in cancer development and progression is widely recognised
(Enoch et al, 1976; Igal, 2011). Although the growing number of
studies on lipid metabolism alterations, this issue still represents a
quite neglected area of cancer research. Indeed, inhibition of
several enzymes involved in fatty acid synthesis, which are
expressed at high levels in malignant cells, impairs cell growth
and promotes apoptosis (Swinnen et al, 2000; Scaglia et al, 2005,
2009; Pandey et al, 2012; Zaidi et al, 2012). This is the case for
SCD1, whose overexpression have been described in several
tumours and transformed cells (Li et al, 1994; Thai et al, 2001;
Scaglia et al, 2009). In breast cancer cells, pharmacological, as well
as genetic inactivation of SCD1 inhibits tumor cell proliferation
and glucose-mediated lipogenesis (Scaglia et al, 2009; Luyimbazi
et al, 2010).
We have previously reported the CAFs’ ability to promote an
increase in plasma membrane fluidity of breast tumor cells
(Angelucci et al, 2012). High SCD1 protein and activity levels,
leading to an increase in MUFA membrane content, are acknowl-
edged to be critical features allowing a more fluid membrane
organisation to be achieved (Stubbs and Smith, 1984; Scaglia et al,
2005). Thus, the CAF-induced upregulation of SCD1 gene and
protein expression that we found in either poorly or highly invasive
tumor cells appears to match the above data well.
Enhanced membrane fluidity, in turn, has been found to
correlate with an increased migratory/invasive activity and
malignant potential of tumor cells, as well as with a poor prognosis
(Nakazawa and Iwaizumi, 1989; Taraboletti et al, 1989; Zeisig et al,
2007). To this regard, we have also described the ability of CAFs to
significantly improve mammary tumor cell migration speed
(Angelucci et al, 2012). In virus-transformed human lung
fibroblasts, as well as in human lung adenocarcinoma cells,
SCD1 knockdown led to a reduction in the anchorage-independent
growth, suggesting a critical role for the desaturase in controlling
cancer cell invasiveness and metastatic potential (Scaglia and Igal,
2005, 2008). Consistent with these findings, herein, we observed a
significantly impaired migratory activity of both MCF-7 and
MDA-MB-231 cells tumor cells as a result of either siRNA-
mediated silencing or pharmacological inhibition of SCD1. On the
basis of the above evidence, we could reasonably assume that the
fibroblast-induced upregulation of SCD1 gene and/or protein
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expression in tumor cells substantially contributes to the previously
observed increases in both cancer cell membrane fluidity and
migration triggered by CAFs (Angelucci et al, 2012).
Given the recognised role of SREBP1 as a powerful activator of
SCD1 gene transcription (Horton et al, 2003; Ettinger et al, 2004),
we investigated the effects of NFs and CAFs on its expression and
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Figure 6. HGF-, TGF-b and bFGF-neutralising antibodies reduce or abolish the NF- and CAF-induced enhancement of cancer cell migration
speed. Cell-tracking experiments were performed on tumor cells co-cultured with NFs or CAFs in the presence of neutralising antibodies to HGF,
TGF-b or bFGF to investigate the contribution of diffusible signals to the fibroblast promotion of tumor cell migration speed. MCF-7 and MDA-MB-
231 cells were cultured for 6 days, alone or in presence of NFs or CAFs, in 35mm glass-bottom Petri dishes and labelled with the CellTracker
Green CMFDA. The cells were incubated in either the presence or the absence of the selected neutralising antibody (anti-HGF, 30mgml 1; anti-
TGF-b, 50mgml 1; anti-bFGF, 10mgml 1) or control nIgGs (50mgml 1). Migration speed of CMFDA-labelled tumor cell was evaluated by using
the ImageJ software plugin ‘Particle Tracker’. HGF, TGF-b and bFGF-neutralising antibodies effectively reduced in MCF-7 (A, C, E) cells or
abolished in MDA-MB-231 cells (B, D, F) the fibroblast-induced increases of tumor cell migration speed. When the three antibodies were
simultaneously added to the co-cultures neither additive nor synergistic effects were observed (G, H). All experiments were run in triplicate and
repeated three times. The data shown are the mean±s.e. 1Po0.05 and 11Po0.001 vs ctrl (MCF-7 or MDA-MB-231 cells cultured alone), yPo0.05
and yyPo0.001 vs MCF-7(þNFs) or MDA-MB-231(þNFs), *Po0.05 and **Po0.001 vs MCF-7(þCAFs) or MDA-MB-231(þCAFs) Student’s t-test.
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ability to bind to the SREs on the SCD1 promoter in tumor cells.
As expected, a significant increase in SREBP1 level and activity
was induced, notably by CAFs, in the poorly invasive MCF-7
cells. The crucial involvement of SREBP1 in the induction of
SCD1 levels promoted particularly by CAFs in mammary tumor
cells is even more clearly demonstrated by the results of SREBP1
pharmacological inhibition which, in MCF-7 cells, led to the
disappearance of the SCD1 upregulation promoted by CAF-
derived paracrine signalings. A similar concomitant regulation of
SCD1 and SREBP1 has also been described in the same cell
model by other authors who found that the rapamycin-mediated
inhibition of mTOR signalling led to a decrease in SCD1
transcript and protein levels, as well as in SREBP1 expression
and DNA binding activity (Luyimbazi et al, 2010). Interestingly,
in several human normal and neoplastic cell lines, including
MDA-MB-468 breast cancer cells, impairment of mTOR path-
way by rapamycin was found to inhibit cell motility or invasion
(Zhou and Huang, 2011). These findings support the existence of
a fil rouge linking SREBP1/SCD1-dependent regulation of fatty
acids membrane composition of breast tumor cells to their
migratory behaviour. Unexpectedly, in the highly aggressive
MDA-MB-231 cells, despite a fibroblast-promoted enhancement
of SREBP1 DNA binding activity, a sharp reduction in the
protein level was induced by both NFs and CAFs. This apparent
discrepancy between SREBP1 expression and activity may be
consistent with a hyperactivation of the residual protein
counterbalancing its scarceness. A dual regulation of the
expression of SREBP1 and its downstream effector SCD1 has
been previously described in prostate cancer tissue specimens
where high and low levels of SREBP1 and SCD1, respectively,
have been detected (Ettinger et al, 2004; Moore et al, 2005). Also,
it should be considered that MDA-MB-231 are poorly-differ-
entiated cells, displaying a mesenchymal-like phenotype. If, on
the one hand, this feature supports their invasive behaviour, on
the other hand, it could lead to gene and protein dysregulation, if
compared with well-differentiated breast tumor cells (Neve et al,
2006). Thus, in this cell model, also SREBP1 independent
mechanisms may partly account for SCD1 upregulation. Indeed,
in support of this hypothesis, we found that the inhibition of
SREBP1 activation by Fatostatin in MDA-MB-231 cells failed to
produce any significant effect on the increase in SCD1 protein
levels induced by CAF-secreted factors.
In various human nonmalignant cells SCD1 has been found to
be a target of hormones and growth factors, including TGF-b and
bFGF, which upregulate the desaturase expression (Samuel et al,
2002; Demoulin et al, 2004). The crucial role played by CAF-
derived diffusible signals in controlling cancer cell migration and
invasiveness has been also well-established (Bhowmick et al, 2004;
De Wever et al, 2008). Therefore, we investigated the alleged
contribution to the fibroblast-mediated increase in cancer cell
migration speed of three CAF-released growth factors which are
believed to greatly influence tumor spread, such as HGF, TGF-b or
bFGF (Bhowmick et al, 2004; De Wever et al, 2008). The antibody-
mediated neutralization of these endogenous growth factors in
cancer cell/fibroblast co-cultures respectively reduced or abolished
the stimulatory effect produced notably by CAFs on MCF-7 and
MDA-MB-231 cell migration speed. These findings suggest a
relevant impact of the CAF-released signals on the improvement of
the tumor cell migratory ability induced by fibroblasts. SCD1
activity seems to have a crucial role in eliciting such effect, as
demonstrated by the complete suppression of the increase in tumor
cell migration induced by the exposure to the CAF-CM, as a result
of the SCD1 pharmacological inhibition. Nevertheless, the lack of a
complete abolition of the fibroblast stimulatory effect in the poorly
invasive MCF-7 cells provides evidence of a more complex
signalling network responsible for CAF-promoted tumor cell
migration in welldifferentiated/low aggressive breast cancers.
Further, we found that the highly invasive MDA-MB-231 cells
are able to produce a certain amount of HGF, TGF-b or bFGF,
which slightly influenced their migratory speed. Thus, the
suppressive effects observed in the presence of neutralising
antibodies may be also owing to the inhibition of these autocrine
loops. A possible CAF-triggered secretion of HGF, TGF-b or bFGF
by cancer cells cannot be excluded as a contributory cause of the
observed effects. Production of large amounts of the HGF activator
(HGFA), stimulating expression of HGF in stromal cells, has been
previously demonstrated in highly invasive breast cancer cells such
as MDA-MB-231 that also overexpress the HGF receptor c-met.
Conversely, the poorly invasive MCF-7 cells displayed low levels of
c-met and HGFA (Parr and Jiang, 2006). Ribozyme transgenes
targeting of HGF in human fibroblasts or c-met in MDA-MB-231
tumor cells resulted in a reduction of mammary cancer cells
in vitro invasiveness (Jiang et al, 2003). Normal mammary
fibroblasts engineered to secrete HGF have been reported to
increase invasiveness of c-met expressing human ductal carcinoma
in situ (DCIS) cells in vitro and promote the in vivo transition of
nude mice DCIS cell xenografts to invasive carcinomas (Jedeszko
et al, 2009). Likewise, forced overexpression of HGF or TGF-b in
human mammary fibroblasts can induce human mammary
epithelia to develop outgrowths indistinguishable from invasive
breast carcinomas (Kuperwasser et al, 2004). Consistent with our
findings, migration and scattering of the human metastatic breast
cancer cells MCF10CA1a has been demonstrated to be dependent
on TGF-b secretion by normal murine dermal fibroblasts (Stuelten
et al, 2010).
Compelling evidence has also been provided of the influence of
CAF-derived bFGF on mammary cancer hormone-independent
growth (Giulianelli et al, 2008). In cultured human breast cancer
cells, including MDA-MB-231, bFGF has been found to induce
migration whereas a correlation between bFGF expression in
stromal fibroblasts and high tumor invasiveness has also been
described in other cancer types, such as oral squamous-cell
carcinoma (Hase et al, 2006).
In summary, our study provides additional information to help
define the molecular basis of the migration-promoting role of
CAFs in breast cancer. In the complex network of epithelium-
stroma interaction, the identification of further elements in the
CAF-regulated signalling axis controlling mammary cancer cells
migration may offer new molecular objectives. Notably, the
relevant inhibitory effects produced by SCD1 depletion on
mammary cancer cells migration further consolidate the role of
this enzyme as one of the convincing future candidate therapeutic
target. It is worth mentioning that NFs, used as a ‘normal’ control
to evaluate the CAFs’ impact on cancer cells, triggered overall
similar effects as those mediated by CAFs, even though at a lesser
extent. This could be ascribable to the probable alterations that
these normal cells may go through during their cohabitation in co-
culture with neoplastic cells.
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